Curated News
By: NewsRamp Editorial Staff
October 14, 2025
TransCode's Cancer Drug Shows Promise in Phase 1 Trial
TLDR
- TransCode's TTX-MC138 Phase 1a success positions it ahead in metastatic cancer treatment with 44% stable disease rate and clear path to Phase 2.
- TransCode's TTX-MC138 Phase 1a trial established safety in 16 patients with no toxicities and determined the optimal dose for Phase 2 testing.
- This RNA therapy brings new hope for metastatic cancer patients by targeting specific biomarkers to potentially extend and improve lives.
- TransCode's nanoparticle platform delivers RNA therapeutics that inhibit cancer-spreading microRNA-10b, representing a novel approach to treating metastatic disease.
Impact - Why it Matters
This development represents a crucial advancement in metastatic cancer treatment, potentially offering new hope for patients with limited therapeutic options. The successful targeting of microRNA-10b, a key biomarker of metastasis, could lead to more effective treatments for cancers that have spread throughout the body. Given that metastasis accounts for the vast majority of cancer-related deaths, any progress in this area has profound implications for patient survival and quality of life. The RNA-based approach also demonstrates the growing potential of genetic medicine in oncology, potentially opening doors to treating other difficult cancers. For investors and the medical community, this signals continued innovation in biotech and the expanding role of RNA therapeutics beyond current applications.
Summary
TransCode Therapeutics (NASDAQ: RNAZ) has achieved a significant milestone in cancer treatment development with the successful completion of its Phase 1a clinical trial for TTX-MC138, an investigational inhibitor targeting microRNA-10b. The trial demonstrated excellent safety results with no significant safety events or dose-limiting toxicities observed across all sixteen treated patients, successfully meeting its primary safety endpoint. Remarkably, 44% of patients achieved stable disease lasting four months or longer, indicating promising therapeutic potential for this novel RNA-based treatment approach. The favorable safety profile, durability of response, and pharmacodynamic data have established a recommended Phase 2 dose, paving the way for advancement into a Phase 2a trial to further assess efficacy across multiple metastatic cancer indications.
TransCode Therapeutics represents a clinical-stage oncology company dedicated to defeating cancer through intelligent design and effective delivery of RNA therapeutics based on its proprietary TTX nanoparticle platform. The company's lead candidate, TTX-MC138, specifically targets metastatic tumors that overexpress microRNA-10b, a well-documented and unique biomarker of metastasis. Beyond this promising candidate, TransCode maintains a robust portfolio of other first-in-class RNA therapeutic candidates designed to overcome the longstanding challenges of RNA delivery, potentially unlocking access to various novel genetic targets relevant to treating multiple cancer types. The company's progress represents a significant step forward in the broader field of RNA therapeutics and metastatic cancer treatment.
The announcement was distributed through BioMedWire, a specialized communications platform within the Dynamic Brand Portfolio that focuses on biotechnology, biomedical sciences, and life sciences sectors. BioMedWire provides comprehensive corporate communications solutions including wire distribution, article syndication to thousands of outlets, press release enhancement, and social media distribution through IBN's extensive network. This platform ensures that breaking news and developments in the biotech sector reach investors, influencers, consumers, and the general public effectively, cutting through information overload to provide unparalleled recognition and brand awareness for companies like TransCode Therapeutics operating in this dynamic and rapidly evolving field.
Source Statement
This curated news summary relied on content disributed by InvestorBrandNetwork (IBN). Read the original source here, TransCode's Cancer Drug Shows Promise in Phase 1 Trial
